Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Meet us at BiotechShowcase via PartneringOne https://informaconnect.com/biotech-showcase/partnering/
GALEXI™ is the first technology of its type globally for a major bioanalytics company.
The GALEXI™ client portal is particularly valuable for international clients working across different time zones requiring instant access to real-time study management.
The highly secure portal has undergone extensive live testing with a number of US clients and will now be offered to all clients.
Agilex Biolabs, which has a 24-year track-record, is known internationally for its continued investment in the latest technology, and for attracting some of the leading scientists from Australia and around the world.
Agilex Biolabs CEO Jason Valentine said:
“GALEXI™ is part of our technology focus where we have invested heavily in the latest platforms that our clients expect from a world-class biolabs facility.
We offer the most advanced laboratory technologies including Sciex API 6500+ LC-MS/MS systems, Sciex API 4000 LC-MS/MS systems, Gyrolab™ Xplore, Luminex MAGPIX xPONENT ™, MSD Quickplex 120 and BD FACSymphony™ A3 20 colour flow cytometry analysers, so we have the capability to deliver any sized project.
Agilex Biolabs also has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.
Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.
Australia has led the world in keeping COVID-19 numbers down to almost zero across the country by acting swiftly to minor outbreaks.
We have extensive COVID protocols in place to respond immediately to circuit breakers, ensuring safety for our team and business as usual for our clients.”
Agilex Biolabs, the only FDA-inspected lab of its type in the region, also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.
The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA.
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics servicesthat include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
· Immunophenotyping
- Receptor occupancy
· Cytokine release assays (whole blood or PBMC stimulation assays) and
cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays (eg: ADCC)
Agilex Biolabs has more than 100 staff which includes 75 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs companies from US, Europe and APAC.
